Advertisement
Screener

Celularity Inc. (CELU) Operating Cash Flow

2.8 / 5 stars · 68/120 Roast Me

Celularity Inc. Operating Cash Flow

Celularity Inc. (CELU) reported Operating Cash Flow of -$13.25 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-30.

Financial Statements › Cash Flow › Operating Activities

us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-04-30

  • Celularity Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.10M, a 420.14% decline year-over-year.
  • Celularity Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.16M.
  • Celularity Inc. net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was -$999.00K.
  • Celularity Inc. net cash provided by (used in) operating activities for the quarter ending 2025-03-31 was -$2.99M.
  • Celularity Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$13.25M.
  • Celularity Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$6.40M.
  • Celularity Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$38.69M.
  • Celularity Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$137.88M.
Period endNet Cash Provided by (Used in) Operating Activities 1 monthNet Cash Provided by (Used in) Operating Activities 3 monthNet Cash Provided by (Used in) Operating Activities 3 month as first filedNet Cash Provided by (Used in) Operating Activities 4 monthNet Cash Provided by (Used in) Operating Activities 6 monthNet Cash Provided by (Used in) Operating Activities 6 month as first filedNet Cash Provided by (Used in) Operating Activities 9 monthNet Cash Provided by (Used in) Operating Activities 9 month as first filedNet Cash Provided by (Used in) Operating Activities 12 monthNet Cash Provided by (Used in) Operating Activities 12 month as first filed
2025-12-31-$5.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30
-$9.26M
derived: sum of 2 quarters · filed 2026-04-30
-$10.26M
derived: sum of 3 quarters · filed 2026-04-30
-$13.25M
10-K · filed 2026-04-30
2025-09-30-$4.16M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
-$5.16M
derived: sum of 2 quarters · filed 2025-11-14
-$8.15M
10-Q · filed 2025-11-14
-$6.56M
derived: sum of 4 quarters · filed 2026-04-30
2025-06-30-$999.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29
-$3.99M
10-Q · filed 2025-08-29
-$2.40M
derived: sum of 3 quarters · filed 2026-04-30
-$2.54M
derived: sum of 4 quarters · filed 2026-04-30
2025-03-31-$2.99M
10-Q · filed 2025-08-29
-$1.40M
derived: sum of 2 quarters · filed 2026-04-30
-$1.54M
derived: sum of 3 quarters · filed 2026-04-30
-$4.99M
derived: sum of 4 quarters · filed 2026-04-30
2024-12-31$1.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-30
$1.45M
derived: sum of 2 quarters · filed 2026-04-30
-$2.00M
derived: sum of 3 quarters · filed 2026-04-30
-$6.40M
10-K · filed 2026-04-30
2024-09-30-$144.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14
-$3.59M
derived: sum of 2 quarters · filed 2025-11-14
-$8.00M
10-Q · filed 2025-11-14
-$12.34M
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30-$3.45M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-29
-$7.85M
10-Q · filed 2025-08-29
-$12.19M
derived: sum of 3 quarters · filed 2025-08-29
-$20.51M
derived: sum of 4 quarters · filed 2025-08-29
2024-03-31-$4.40M
10-Q · filed 2025-08-29
-$8.74M
derived: sum of 2 quarters · filed 2025-08-29
-$17.07M
derived: sum of 3 quarters · filed 2025-08-29
-$28.09M
derived: sum of 4 quarters · filed 2025-08-29
2023-12-31-$4.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-05-08
-$12.66M
derived: sum of 2 quarters · filed 2025-05-08
-$23.69M
derived: sum of 3 quarters · filed 2025-05-08
-$38.69M
10-K · filed 2025-05-08
2023-09-30-$8.32M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-12-06
-$19.35M
derived: sum of 2 quarters · filed 2024-12-06
-$34.34M
10-Q · filed 2024-12-06
-$63.93M
derived: sum of 4 quarters · filed 2024-12-06
2023-06-30-$11.03M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-11-07
-$26.02M
10-Q · filed 2024-11-07
-$55.61M
derived: sum of 3 quarters · filed 2024-11-07
-$93.33M
derived: sum of 4 quarters · filed 2024-11-07
2023-03-31-$14.99M
10-Q · filed 2024-10-16
-$44.58M
derived: sum of 2 quarters · filed 2024-10-16
-$82.30M
derived: sum of 3 quarters · filed 2024-10-16
-$118.62M
derived: sum of 4 quarters · filed 2024-10-16
2022-12-31-$29.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-07-30
-$67.31M
derived: sum of 2 quarters · filed 2024-07-30
-$103.62M
derived: sum of 3 quarters · filed 2024-07-30
-$137.88M
10-K · filed 2024-07-30
2022-09-30-$37.72M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-01-03
-$74.04M
derived: sum of 2 quarters · filed 2024-01-03
-$108.29M
10-Q · filed 2024-01-03
-$140.34M
derived: sum of 4 quarters · filed 2024-01-03
2022-06-30-$36.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14
-$70.57M
10-Q · filed 2023-08-14
-$102.62M
derived: sum of 3 quarters · filed 2023-08-14
-$137.39M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$34.25M
10-Q · filed 2023-05-22
-$66.30M
derived: sum of 2 quarters · filed 2023-05-22
-$101.07M
derived: sum of 3 quarters · filed 2023-05-22
-$119.27M
derived: sum of 4 quarters · filed 2023-05-22
2021-12-31-$32.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31
-$66.82M
derived: sum of 2 quarters · filed 2023-03-31
-$85.02M
derived: sum of 3 quarters · filed 2023-03-31
-$110.10M
10-K · filed 2023-03-31
2021-09-30-$34.77M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10
-$52.97M
derived: sum of 2 quarters · filed 2022-11-10
-$78.05M
10-Q · filed 2022-11-10
-$94.88M
derived: sum of 4 quarters · filed 2022-11-10
2021-06-30-$18.20M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09
-$43.28M
10-Q · filed 2022-08-09
-$828.94K
10-Q · filed 2021-08-19
-$60.11M
derived: sum of 3 quarters · filed 2022-08-09
-$105.70M
derived: sum of 4 quarters · filed 2022-08-09
2021-03-31-$25.08M
10-Q · filed 2022-05-16
-$446.09K
10-Q · filed 2021-05-24
-$41.91M
derived: sum of 2 quarters · filed 2022-05-16
-$87.50M
derived: sum of 3 quarters · filed 2022-05-16
-$87.72M
derived: sum of 4 quarters · filed 2022-05-16
2020-12-31-$16.83M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31
-$62.42M
derived: sum of 2 quarters · filed 2022-03-31
-$62.64M
derived: sum of 3 quarters · filed 2022-03-31
-$63.19M
10-K · filed 2022-03-31
-$1.18M
10-K · filed 2021-03-04
2020-09-30-$45.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
-$45.81M
derived: sum of 2 quarters · filed 2021-11-12
-$46.36M
10-Q · filed 2021-11-12
-$938.71K
10-Q · filed 2020-11-16
-$46.59M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$224.43K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-19
-$774.01K
10-Q · filed 2021-08-19
-$997.81K
derived: sum of 3 quarters · filed 2021-08-19
-$1.68M
derived: sum of 4 quarters · filed 2021-08-19
2020-03-31-$549.58K
10-Q · filed 2021-05-24
-$773.38K
derived: sum of 2 quarters · filed 2021-05-24
-$1.45M
derived: sum of 3 quarters · filed 2021-05-24
-$1.65M
derived: sum of 4 quarters · filed 2021-05-24
2019-12-31-$223.80K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-05-24
-$903.02K
derived: sum of 2 quarters · filed 2021-05-24
-$1.10M
derived: sum of 3 quarters · filed 2021-05-24
-$1.10M
10-K/A · filed 2021-05-24
2019-09-30-$679.22K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-16
-$873.35K
derived: sum of 2 quarters · filed 2020-11-16
-$874.03K
10-Q · filed 2020-11-16
2019-06-30-$194.13K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13
-$194.81K
10-Q · filed 2020-08-13
2019-03-31-$676.00
10-Q · filed 2020-05-15
2018-12-31-$543.00
10-K · filed 2020-03-24
2018-09-30-$545.00
10-Q · filed 2019-11-13

Similar stocks

Stock NameCountryMarket CapPE Ratio
CervoMed Inc. (CRVO)United States$0.038B-1.39
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
PMGC Holdings Inc. (ELAB)United States$0.037B
Edesa Biotech, Inc. (EDSA)Canada$0.039B
BriaCell Therapeutics Corp. (BCTX)$0.037B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Incannex Healthcare Inc. (IXHL)$0.040B-22.32